CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This ...

Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top candidates in ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...

Tempus AI (TEM), announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms ...

Tempus AI (TEM) launched an AI algorithm identifying cancer patients responsive to platinum-based chemotherapy using RNA analysis. Tempus reported preliminary Q4 revenue of $367M, up 83% ...

Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for ...